Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,propertyPlantEquipment,totalCurrentAssets,netReceivables,longTermDebt,inventory,accountsPayable,otherLiab,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,market,currency,twoHundredDayAverageChangePercent,exchangeDataDelayedBy,marketState,exchange,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,gmtOffSetMilliseconds,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,shortName,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry
t0,ISCO,-5945000.0,7769090,172000,,-599000,,-599000,1438000,1043000,-567000,-567000,,-32000,,,,0,1658000,2225000,615000,-32000,,-599000,-599000,1242000.0,105003000.0,6417000.0,-4703000.0,250000.0,6019000.0,8000.0,-109714000.0,434000.0,1117000.0,4721000.0,3071000.0,1297000.0,3046000.0,437000.0,915000.0,1055000.0,512000.0,,152000.0,-2000.0,824000.0,824000.0,-158000.0,428000.0,-394000.0,66000.0,-151000.0,-34000.0,330000.0,,-1675000.0,en-US,US,EQUITY,False,Delayed Quote,us_market,USD,0.03308381,0,PRE,PNK,False,False,0.62,1630438644,0.0,0.495,0.62,0.62,34,-0.70454544,-0.99358976,15,America/New_York,EDT,4,0.0,0.62 - 0.62,0.62,0.0,0.0,0,0,finmb_30918491,Other OTC,International Stem Cell Corporation,USD,15248,6414,0.32,1.0666666,0.3 - 1.08,-0.46000004,-0.42592594,0.3,1.08,1592596800,1592596800,1592596800,-0.391,-0.88,-14400000,-0.624,0.566,0.05400002,0.0954064,0.6001449,0.019855082,4816836,INTERNATIONAL STEM CELL CORPORA,0.71,,,1.08,0.3,0.566,0.6001,15.25k,6.41k,7.77M,,3.59M,55.40%,0.00%,,,,,,,,,,,0.00%,,,1:150,"Jul 28, 2015","Dec 30, 2020","Mar 30, 2021",-45.91%,-44.58%,-27.77%,-557.13%,6.43M,0.85,-29.70%,4.35M,-2.61M,-2.95M,-0.3910,,1.12M,0.14,5.09M,,0.64,-0.62,-1M,-18.75k,Value,92008,Healthcare,33,"International Stem Cell Corporation focuses on the development of therapeutic and biomedical products worldwide. The company's products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. It develops various cell types, including neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; liver cells to treat various congenital and acquired liver diseases; and islet cells for the treatment of diabetes. The company also develops, manufactures, and markets skincare products and human cell culture products. Its human cell culture products include human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. The company's human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. It sells skincare products through a website and professional channels; and human cell culture products through its sales force, OEM partners, and brand distributors. The company was incorporated in 2005 and is headquartered in Carlsbad, California.",Carlsbad,760 940 6383,CA,1609372800,United States,http://www.internationalstemcell.com,86400,5950 Priestly Drive,760 476 0600,Biotechnology
t-1,ISCO,-5600000.0,7769090,-98000,,-721000,,-721000,1664000,833000,-733000,-733000,,-28000,,,,0,1476000,2209000,643000,12000,,-721000,-721000,1262000.0,104769000.0,5320000.0,-4338000.0,250000.0,5287000.0,8000.0,-109115000.0,434000.0,689000.0,1483000.0,141000.0,1408000.0,2183000.0,403000.0,2992000.0,917000.0,360000.0,,-31000.0,-26000.0,824000.0,824000.0,-75000.0,-337000.0,-311000.0,61000.0,68000.0,106000.0,281000.0,-4000.0,700000.0,en-US,US,EQUITY,False,Delayed Quote,us_market,USD,0.03308381,0,PRE,PNK,False,False,0.62,1630438644,0.0,0.495,0.62,0.62,34,-0.70454544,-0.99358976,15,America/New_York,EDT,4,0.0,0.62 - 0.62,0.62,0.0,0.0,0,0,finmb_30918491,Other OTC,International Stem Cell Corporation,USD,15248,6414,0.32,1.0666666,0.3 - 1.08,-0.46000004,-0.42592594,0.3,1.08,1592596800,1592596800,1592596800,-0.391,-0.88,-14400000,-0.624,0.566,0.05400002,0.0954064,0.6001449,0.019855082,4816836,INTERNATIONAL STEM CELL CORPORA,0.71,,,1.08,0.3,0.566,0.6001,15.25k,6.41k,7.77M,,3.59M,55.40%,0.00%,,,,,,,,,,,0.00%,,,1:150,"Jul 28, 2015","Dec 30, 2020","Mar 30, 2021",-45.91%,-44.58%,-27.77%,-557.13%,6.43M,0.85,-29.70%,4.35M,-2.61M,-2.95M,-0.3910,,1.12M,0.14,5.09M,,0.64,-0.62,-1M,-18.75k,Value,92008,Healthcare,33,"International Stem Cell Corporation focuses on the development of therapeutic and biomedical products worldwide. The company's products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. It develops various cell types, including neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; liver cells to treat various congenital and acquired liver diseases; and islet cells for the treatment of diabetes. The company also develops, manufactures, and markets skincare products and human cell culture products. Its human cell culture products include human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. The company's human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. It sells skincare products through a website and professional channels; and human cell culture products through its sales force, OEM partners, and brand distributors. The company was incorporated in 2005 and is headquartered in Carlsbad, California.",Carlsbad,760 940 6383,CA,1609372800,United States,http://www.internationalstemcell.com,86400,5950 Priestly Drive,760 476 0600,Biotechnology
t-2,ISCO,-5147000.0,7769090,255000,,-544000,,-544000,1396000,918000,-733000,-733000,,-28000,,,,0,1481000,2214000,563000,189000,,-544000,-544000,1266000.0,104505000.0,5427000.0,-3881000.0,250000.0,5851000.0,8000.0,-108394000.0,447000.0,1026000.0,3852000.0,2505000.0,1507000.0,2631000.0,509000.0,599000.0,937000.0,391000.0,40000.0,-188000.0,-12000.0,824000.0,824000.0,11000.0,-289000.0,-277000.0,64000.0,17000.0,185000.0,178000.0,-2000.0,-1221000.0,en-US,US,EQUITY,False,Delayed Quote,us_market,USD,0.03308381,0,PRE,PNK,False,False,0.62,1630438644,0.0,0.495,0.62,0.62,34,-0.70454544,-0.99358976,15,America/New_York,EDT,4,0.0,0.62 - 0.62,0.62,0.0,0.0,0,0,finmb_30918491,Other OTC,International Stem Cell Corporation,USD,15248,6414,0.32,1.0666666,0.3 - 1.08,-0.46000004,-0.42592594,0.3,1.08,1592596800,1592596800,1592596800,-0.391,-0.88,-14400000,-0.624,0.566,0.05400002,0.0954064,0.6001449,0.019855082,4816836,INTERNATIONAL STEM CELL CORPORA,0.71,,,1.08,0.3,0.566,0.6001,15.25k,6.41k,7.77M,,3.59M,55.40%,0.00%,,,,,,,,,,,0.00%,,,1:150,"Jul 28, 2015","Dec 30, 2020","Mar 30, 2021",-45.91%,-44.58%,-27.77%,-557.13%,6.43M,0.85,-29.70%,4.35M,-2.61M,-2.95M,-0.3910,,1.12M,0.14,5.09M,,0.64,-0.62,-1M,-18.75k,Value,92008,Healthcare,33,"International Stem Cell Corporation focuses on the development of therapeutic and biomedical products worldwide. The company's products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. It develops various cell types, including neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; liver cells to treat various congenital and acquired liver diseases; and islet cells for the treatment of diabetes. The company also develops, manufactures, and markets skincare products and human cell culture products. Its human cell culture products include human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. The company's human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. It sells skincare products through a website and professional channels; and human cell culture products through its sales force, OEM partners, and brand distributors. The company was incorporated in 2005 and is headquartered in Carlsbad, California.",Carlsbad,760 940 6383,CA,1609372800,United States,http://www.internationalstemcell.com,86400,5950 Priestly Drive,760 476 0600,Biotechnology
t-3,ISCO,-4955000.0,7769090,200000,,-1086000,,-1086000,1725000,1093000,-832000,-832000,,-29000,,,,0,1812000,2644000,719000,-254000,,-1086000,-1086000,1345000.0,104232000.0,6088000.0,-3610000.0,250000.0,6783000.0,8000.0,-107850000.0,427000.0,1315000.0,4081000.0,2422000.0,1613000.0,3398000.0,694000.0,654000.0,1010000.0,579000.0,322000.0,45000.0,-29000.0,654000.0,654000.0,-232000.0,607000.0,-18000.0,65000.0,154000.0,444000.0,592000.0,-19000.0,-683000.0,en-US,US,EQUITY,False,Delayed Quote,us_market,USD,0.03308381,0,PRE,PNK,False,False,0.62,1630438644,0.0,0.495,0.62,0.62,34,-0.70454544,-0.99358976,15,America/New_York,EDT,4,0.0,0.62 - 0.62,0.62,0.0,0.0,0,0,finmb_30918491,Other OTC,International Stem Cell Corporation,USD,15248,6414,0.32,1.0666666,0.3 - 1.08,-0.46000004,-0.42592594,0.3,1.08,1592596800,1592596800,1592596800,-0.391,-0.88,-14400000,-0.624,0.566,0.05400002,0.0954064,0.6001449,0.019855082,4816836,INTERNATIONAL STEM CELL CORPORA,0.71,,,1.08,0.3,0.566,0.6001,15.25k,6.41k,7.77M,,3.59M,55.40%,0.00%,,,,,,,,,,,0.00%,,,1:150,"Jul 28, 2015","Dec 30, 2020","Mar 30, 2021",-45.91%,-44.58%,-27.77%,-557.13%,6.43M,0.85,-29.70%,4.35M,-2.61M,-2.95M,-0.3910,,1.12M,0.14,5.09M,,0.64,-0.62,-1M,-18.75k,Value,92008,Healthcare,33,"International Stem Cell Corporation focuses on the development of therapeutic and biomedical products worldwide. The company's products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. It develops various cell types, including neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; liver cells to treat various congenital and acquired liver diseases; and islet cells for the treatment of diabetes. The company also develops, manufactures, and markets skincare products and human cell culture products. Its human cell culture products include human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. The company's human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. It sells skincare products through a website and professional channels; and human cell culture products through its sales force, OEM partners, and brand distributors. The company was incorporated in 2005 and is headquartered in Carlsbad, California.",Carlsbad,760 940 6383,CA,1609372800,United States,http://www.internationalstemcell.com,86400,5950 Priestly Drive,760 476 0600,Biotechnology
